-
EP4121069
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4121069
| EP4121069 - INJECTABLE FORMULATION OF POLY(LACTIC-CO-GLYCOLIC (PLGA)) MICROSPHERES ENCAPSULATING SILTUXIMAB [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 23.12.2022 Database last updated on 15.06.2024 | |
| Former | The international publication has been made Status updated on 24.09.2021 | Most recent event Tooltip | 28.03.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Flow Pharma Inc. 201 Redwood Shores Suite 200 Redwood City CA 94065 / US | [2023/04] | Inventor(s) | 01 /
RUBSAMEN, Reid M. 19 Orchard Lane Alamno, California 94507 / US | 02 /
BURKHOLTZ, Scott c/o Flow Pharma, Inc. 201 Redwood Shores Parkway Suite 200 Redwood City, California 94065 / US | 03 /
HERST, Charles V. 6389 Westover Driver Oakland, California 94611 / US | 04 /
HODGE, Tom c/o Flow Pharma, Inc. 201 Redwood Shores Parkway Suite 200 Redwood City, California 94065 / US | 05 /
WANG, Lu 1751 Sageland Drive San Jose, California 95131 / US | [2023/04] | Representative(s) | J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | [2023/04] | Application number, filing date | 21770756.1 | 16.03.2021 | [2023/04] | WO2021US22512 | Priority number, date | US202062991456P | 18.03.2020 Original published format: US 202062991456 P | US202062992136P | 19.03.2020 Original published format: US 202062992136 P | US202063041617P | 19.06.2020 Original published format: US 202063041617 P | [2023/04] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021188504 | Date: | 23.09.2021 | Language: | EN | [2021/38] | Type: | A1 Application with search report | No.: | EP4121069 | Date: | 25.01.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 23.09.2021 takes the place of the publication of the European patent application. | [2023/04] | Search report(s) | International search report - published on: | US | 23.09.2021 | Classification | IPC: | A61K35/17, A61K39/00, A61K39/395, A61K45/06, A61K9/00, A61K9/16, A61P11/00, A61P19/02 | [2024/15] | CPC: |
G01N33/6869 (EP,US);
C07K16/248 (EP,US);
A61K47/6883 (US);
A61K9/0019 (EP);
A61K9/1647 (EP);
C07K16/2866 (EP,US);
A61K2039/505 (EP);
A61K2039/54 (EP);
A61K2039/545 (EP);
G01N2333/5412 (EP,US)
(-)
|
| Former IPC [2023/04] | A61K35/17, A61K39/00, A61K39/395, A61K45/06, A61P11/00, A61P19/02 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/04] | Title | German: | INJIZIERBARE FORMULIERUNG VON POLY(MILCHSÄURE-CO-GLYCOLSÄURE (PLGA))-MIKROKÜGELCHEN, DIE SILTUXIMAB EINKAPSELN | [2023/04] | English: | INJECTABLE FORMULATION OF POLY(LACTIC-CO-GLYCOLIC (PLGA)) MICROSPHERES ENCAPSULATING SILTUXIMAB | [2023/04] | French: | FORMULATION INJECTABLE DE MICROSPHÈRES D'ACIDE POLY(LACTIQUE-CO-GLYCOLIQUE) (PLGA) ENCAPSULANT DU SILTUXIMAB | [2023/04] | Entry into regional phase | 18.08.2022 | National basic fee paid | 18.08.2022 | Search fee paid | 18.08.2022 | Designation fee(s) paid | 18.08.2022 | Examination fee paid | Examination procedure | 18.08.2022 | Examination requested [2023/04] | 04.05.2023 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 27.03.2023 | Renewal fee patent year 03 | 27.03.2024 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y]US2007099855 (CINATL JINDRICH [DE]) [Y] 6-8 * entire document *; | [Y]US2014193510 (ELIASOF SCOTT [US], et al) [Y] 4-6, 9, 10, 12-14 * entire document *; | [Y]US2016038596 (WRIGHT JEREMY C [US], et al) [Y] 3, 8, 12, 14 * entire document *; | [A]US2016184330 (SORDILLO PETER P [US], et al) [A] 1-15* entire document *; | [A]WO2017222935 (UNIV KANSAS STATE [US], et al) [A] 1-15 * entire document *; | [Y]WO2019191030 (CLEAR CREEK BIO INC [US]) [Y] 9, 10, 12, 14, 15 * entire document *; | [XY]WO2019217780 (PHOSPHOREX INC [US]) [X] 1,2 * entire document * [Y] 3; | [XY]WO2020023335 (UNIV RUSH MEDICAL CENTER [US]) [X] 11 * entire document * [Y] 4-10, 12-15; | [Y] - Ronco Claudio, Reis Thiago, De rosa Silvia, "Coronavirus Epidemic and Extracorporeal Therapies in Intensive Care: si vis pacem para bellum", Blood Purification, (20200313), vol. 49, no. 3, pages 255 - 258, XP055859398 [Y] 7-10 * . entire document * DOI: http://dx.doi.org/10.1159/000507039 |